|
Associated Malignancies in Patients with Waldenstrom's Macroglobulinemia and Their Kin
|
|
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom's Macroglobulinemia
|
|
Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
|
|
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia
|
|
Hepcidin is Produced by Lymphoplasmacytic Cells and is Associated With Anemia in Waldenstrom's Macroglobulinemia
|
|
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia
|
|
How I treat the acquired von Willebrand syndrome
|
|
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenström macroglobulinemia
|
|
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
|
|
Maintenance Rituximab is associated with improved clinical outcome in rituximab naı¨ve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
|
|
Matrix Metalloproteinase-8 Is Overexpressed in Waldenström's Macroglobulinemia Cells, and Specific Inhibition of this Metalloproteinase Blocks Release of Soluble CD27
|
|
Report from the Sixth International Workshop on Waldenstrom's Macroglobulinemia
|
|
To Treat or Not To Treat, This is the Real Question
|
|
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
|
